GlassScriptPhysician profile
Ashley Brissette
NPI 1366802951
$314,562.99
in general payments reported to CMS, 2019-2025
31 companies · $120K in 2025
The $120K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $19K · 2021: $30K · 2022: $62K · 2023: $46K · 2024: $13K · 2025: $120K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $77K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $77K · Food and Beverage: $16K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,365 · Travel and Lodging: $3,881 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $77,218.08 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76,540.00 |
| Food and Beverage | $15,972.43 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,365.00 |
| Travel and Lodging | $3,880.79 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $98,181.14 | 2019-2025 | Clareon, Tryptyr, Acrysof Iq Vivity |
| Sun Pharmaceutical Industries INC. | $82,432.69 | 2019-2025 | Cequa |
| Alcon Research LLC | $38,875.41 | 2019-2025 | Tryptyr |
| Carl Zeiss Meditec, INC. | $19,200.58 | 2019-2025 | Quatera 700, Forum, Humphrey Hfa |
| Bausch & Lomb Americas INC. | $18,030.75 | 2022-2025 | Blink Nutritears, Ic-8 Apthera Iol, Envista Mx60 Iol |
| Novartis Pharmaceuticals Corporation | $8,411.07 | 2019-2023 | |
| Lumenis Be INC | $8,221.46 | 2025 | M22 |
| Johnson & Johnson Surgical Vision, INC. | $7,582.20 | 2019-2025 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Abbvie INC. | $5,830.93 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $5,372.99 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $4,100.00 | 2021 | |
| Eyevance Pharmaceuticals LLC | $3,519.46 | 2019-2020 | |
| Dompe US, INC. | $2,529.22 | 2019-2025 | Oxervate |
| Ocular Therapeutix, INC. | $2,190.95 | 2019-2023 | Dextenza |
| Quidel Corporation | $1,578.68 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,349.57 | 2019-2020 | |
| Tearlab Corp | $1,325.00 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $1,299.76 | 2019-2022 | |
| Glaukos Corporation | $1,177.68 | 2020-2023 | Kxl System (Not Refurbished) |
| Harrow Eye, LLC | $846.54 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $839.54 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sight Sciences, INC. | $423.30 | 2019-2022 | |
| Rxsight INC | $234.38 | 2021-2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Eyepoint US, INC. | $232.06 | 2019-2020 | |
| Shire North American Group INC | $197.38 | 2019 | |
| Horizon Therapeutics Plc | $157.40 | 2022-2023 | Tepezza |
| Carl Zeiss Meditec USA, INC. | $141.67 | 2024 | |
| Omeros Corporation | $125.00 | 2019 | |
| Ortho-Clinical Diagnostics, INC. | $88.17 | 2024 | Inflammadry |
| Biotissue Holdings INC. | $47.94 | 2025 | |
| Rayner Intraocular Lenses Limited | $20.07 | 2025 | Rayone Spheric, Rayner Cataract Set 1, Rayone Emv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Brissette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.